Erasca reports preliminary success for RAS-targeting pill in pancreatic and lung cancer
Updated
Updated · STAT · Apr 27
Erasca reports preliminary success for RAS-targeting pill in pancreatic and lung cancer
5 articles · Updated · STAT · Apr 27
The ERAS-0015 pill shrank tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer patients in U.S. and China studies.
These early results exceeded company expectations, with Erasca noting the drug's clinical benefit and tolerability compared favorably to Revolution Medicines' daraxonrasib.
While the lung cancer data appears more definitive, the pancreatic cancer results are still maturing but remain highly promising, according to Erasca CEO Jonathan Lim.
Is the hype for this new drug's early data premature against a competitor's proven late-stage success?
Will combining new RAS inhibitors be the ultimate key to controlling these deadly cancers for good?
Could these powerful new cancer drugs one day be used to prevent tumors before they even start?
A $7B drugmaker is challenging a $30B giant. Is this the next major upset in the oncology market?
What makes a 'molecular glue' drug so uniquely effective at destroying these hard-to-treat tumors?